Pomalidomide-5'-PEG8-C2-COOH

• CAT Number: I041019
• CAS Number: 2138440-78-3
• Molecular Formula: C32H47N3O14
• Molecular Weight: 697.73
• Purity: ≥95%
• Synonyms: 3-[2-[2-[2-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid
• InChI: InChI=1S/C32H47N3O14/c36-27-5-4-26(30(39)34-27)35-31(40)24-2-1-3-25(29(24)32(35)41)33-7-9-43-11-13-45-15-17-47-19-21-49-23-22-48-20-18-46-16-14-44-12-10-42-8-6-28(37)38/h1-3,26,33H,4-23H2,(H,37,38)(H,34,36,39)
• InChIKey: KGQVFRREKVWLOE-UHFFFAOYSA-N
• SMILES: C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)NCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)O

Pomalidomide-5′-PEG8-C2-COOH(CAT: I041019) is a conjugate of pomalidomide, a potent immunomodulatory drug, with a polyethylene glycol (PEG) linker. This modification enhances the solubility and bioavailability of pomalidomide, making it more effective in targeting tumor cells. The conjugate’s mechanism of action involves the inhibition of cereblon (CRBN), a component of the E3 ubiquitin ligase complex, leading to the degradation of key proteins involved in cancer cell survival and proliferation. Pomalidomide-5′-PEG8-C2-COOH is particularly effective in the treatment of multiple myeloma and other hematologic malignancies, offering improved pharmacokinetic properties and the potential for reduced off-target effects.